Orphan drug designation plea for Delta-9-Tetrahydrocannibinol and Cannabidiol

Release Date: 10-Oct-2016

PhytoPain Pharma Inc., a part of GrowPros Cannabis Ventures Inc., declares the submission of applications for orphan drug designation status for Delta-9-Tetrahydrocannibinol and Cannabidiol for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS1) and Central PostStroke Pain (CPSP).  Also, it will help in treatment of neuropathic pain associated with cancer, HIV, CPSP, and CRPS1. The aim is to commercialize the drug for the management of uncontrolled pain related to life threatening diseases.


For Orphan Drug Clinical Insight Reports Contact: neeraj@kuickresearch.com

Need custom market research solution? We can help you with that too.